Amarin | AMRN - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 645M 69M 2026-03
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amarin USD 3K 5K 2024-12
AstraZeneca USD 340M 144M 2026-06
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
DBV Technologies USD 461K 323.71K 2025-03
GlaxoSmithKline GBP 121M 46M 2026-06
Halozyme Therapeutics USD 5.51M 597K 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 462M 119M 2026-06